复星医药:收到上交所下发的监管工作函,处理事由是关于复星医药对外投资绿谷医药相关事项,涉及对象是上市公司。不过,此次监管工作函的具体内容并未披露。海思科:子公司上海海思盛诺医药科技有限公司近日收到国家药品监督管理局下发的4个创新药《药物临床试验批准通知书》。这些药品包括HSK45019片、HSK50042片、注射用HSK55718和HSK36357胶囊,分别用于治疗炎症性肠病、呼吸系统疾病、急性...
Source Link复星医药:收到上交所下发的监管工作函,处理事由是关于复星医药对外投资绿谷医药相关事项,涉及对象是上市公司。不过,此次监管工作函的具体内容并未披露。海思科:子公司上海海思盛诺医药科技有限公司近日收到国家药品监督管理局下发的4个创新药《药物临床试验批准通知书》。这些药品包括HSK45019片、HSK50042片、注射用HSK55718和HSK36357胶囊,分别用于治疗炎症性肠病、呼吸系统疾病、急性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.